Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer (DEVELOP)

This study has been completed.
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Centre of Experimental Medicine, Queen Mary University of London
ClinicalTrials.gov Identifier:
NCT01714765
First received: October 17, 2012
Last updated: November 11, 2013
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2012
  Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)